Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Creatine + fluoxetine is a combination of two agents—creatine, a naturally occurring compound involved in cellular energy metabolism, and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) commonly used as an antidepressant. This combination has been studied primarily for its potential to enhance antidepressant effects in the treatment of depression. Preclinical studies suggest that dietary creatine supplementation may augment or accelerate the onset of antidepressant effects when combined with SSRIs like fluoxetine, particularly in females. The mechanism involves both metabolic enhancement (via creatine's role in ATP regeneration and neuroprotection) and serotonergic modulation (via fluoxetine's inhibition of serotonin reuptake). There is evidence from animal models that this combination can produce more robust antidepressant-like behavioral profiles than either agent alone[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on creatine + fluoxetine.